Loading stock data…
MannKind Corporation (MNKD)
$4.16+0.10 (+2.46%)
Market ClosedLast close Sep 8
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MannKind Corporation in the Healthcare sector is trading at $4.16 with a market capitalization of $1.2B. Wall Street consensus targets $7.97 (8 analysts), implying a +91.6% move over the next 12 months. The stock is currently 36% below its 52-week high of $6.51, remaining 0.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +91.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $90.17M↓ | $111.95M↑ | $82.13M↑ | $76.53M↓ | $78.35M |
| Gross Profit | $72.70M↓ | $82.28M↑ | $61.93M↑ | $55.96M↓ | $60.84M |
| Operating Income | -$2.98M↑ | -$7.69M↓ | $18.78M↑ | $10.66M↓ | $24.80M |
| Net Income | -$16.62M↓ | -$15.95M↓ | $7.99M↑ | $668,000↓ | $13.16M |
Peer Comparison
JNJUNHPFE
Fundamentals
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.24B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
40.40%
Volume
Today's trading volume
4.57M
Recent News
MannKind (MNKD) Could Be 48% Undervalued Following Its Afrezza And Pipeline Narrative
MannKind (MNKD) continues to draw attention after recent share price moves, with the stock closing at US$3.95. Investors are weighing its current market value of about US$1.31b against its latest financial profile. Over the past year, MannKind’s share price return has been weak compared with its recent 30 day and 90 day share price returns of 2.60% and 4.77%, while the 1 year total shareholder return declined 13.94%. This suggests that recent momentum is still trying to repair longer term...
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.
MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says
MannKind's (MNKD) increasingly diversified portfolio is seen bringing in higher revenue in H2, with
United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.
MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts ...
MannKind Corp (MNKD) reports 43% revenue surge to $109.4 million, fueled by Furosix momentum and Afrezza pediatric launch, despite a GAAP net loss.